Roche Holding AG - 15 Year Stock Price History | RHHBY
Historical daily share price chart and data for Roche Holding AG since 2011 adjusted for splits and dividends. The latest closing stock price for Roche Holding AG as of May 14, 2026 is 51.28.
- The all-time high Roche Holding AG stock closing price was 58.72 on February 24, 2026.
- The Roche Holding AG 52-week high stock price is 60.85, which is 18.7% above the current share price.
- The Roche Holding AG 52-week low stock price is 37.51, which is 26.9% below the current share price.
- The average Roche Holding AG stock price for the last 52 weeks is 46.74.
| Roche Holding AG Historical Annual Stock Price Data | ||||||
|---|---|---|---|---|---|---|
| Year | Average Stock Price | Year Open | Year High | Year Low | Year Close | Annual % Change |
| 2026 | 52.3923 | 49.8717 | 58.7217 | 47.3900 | 51.2800 | 2.58% |
| 2025 | 40.1942 | 32.7782 | 50.9768 | 32.7782 | 49.9880 | 52.77% |
| 2024 | 33.1409 | 32.7128 | 39.7109 | 27.4496 | 32.7219 | 0.36% |
| 2023 | 33.0100 | 34.0758 | 36.3485 | 29.0950 | 32.6048 | -4.02% |
| 2022 | 37.6511 | 43.6470 | 46.3715 | 33.1560 | 33.9716 | -22.21% |
| 2021 | 38.6693 | 35.9574 | 44.1878 | 32.8763 | 43.6724 | 21.57% |
| 2020 | 34.8900 | 32.4845 | 38.3829 | 28.3296 | 35.9246 | 11.22% |
| 2019 | 27.5430 | 23.6922 | 32.3574 | 23.6922 | 32.3018 | 35.07% |
| 2018 | 22.6190 | 23.5424 | 25.0157 | 20.3065 | 23.9153 | 2.16% |
| 2017 | 23.1448 | 20.7776 | 25.5215 | 20.7776 | 23.4089 | 14.28% |
| 2016 | 22.1426 | 23.7559 | 24.1735 | 19.4422 | 20.4832 | -14.53% |
| 2015 | 23.9613 | 22.8311 | 26.7384 | 21.8549 | 23.9644 | 4.72% |
| 2014 | 24.4484 | 22.4353 | 25.6320 | 21.7296 | 22.8850 | -0.22% |
| 2013 | 20.2951 | 16.1733 | 23.0267 | 16.1512 | 22.9352 | 44.06% |
| 2012 | 14.0750 | 13.0926 | 16.1922 | 12.2513 | 15.9211 | 23.95% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $318.782B | $76.450B |
| Basel, Switzerland-based Roche Holding Ltd. is a leading health care company focused on developing and commercializing innovative diagnostic and therapeutic products and services, which enable early detection and prevention of diseases as well as their treatment and monitoring. The company conducts its operations through two segments ' Pharmaceuticals and Diagnostics.Pharmaceuticals: Key focus areas in this segment include Oncology, Virology, Inflammation, Metabolism and Neuroscience. Diagnostics: The Diagnostics Division operates in four segments ' Roche Professional Diagnostics, Roche Diabetes Care, Roche Molecular Diagnostics, and Roche Tissue Diagnostics. In September 2014, Roche acquired InterMune for $8.3 billion and added Esbriet to its portfolio. During the first quarter of 2018, Roche acquired Flatiron Health and Ignyta, Inc. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |